Research Programs-Radiobiology and Radiotherapy

研究项目-放射生物学和放射治疗

基本信息

批准号：
8132523
负责人：
PETER M GLAZER
金额：
$ 3.34万
依托单位：
YALE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/8132523
关键词：
ATM activation Address Alkylating Agents Alkylation Alternative Medicine American American Cancer Society Animal Model Animals Apoptosis Area Attention Award B-Cell Lymphomas BRCA1 gene BRCA2 gene Bacteria Base Excision Repairs Biogenesis Biological Biological Models Biology Biotechnology Bone Marrow Botanicals Brachytherapy Breast Breast Cancer Treatment CDT1 Gene Caenorhabditis elegans Cancer Center Cell Communication Cell Cycle Cell Nucleus Cells Cellular biology Center Core Grants Cervix Uteri Cervix carcinoma Chinese People Chromosomes Cimicifuga racemosa Cisplatin Clinical Clinical Research Clinical Trials Clonal Expansion Collaborations Complex Cutaneous Cutaneous Lymphoma Cyclin A Cytotoxin DNA DNA Binding DNA Damage DNA Repair DNA Repair Enzymes DNA Repair Gene DNA Structure DNA photoproducts DNA-dependent protein kinase Databases Development Developmental Therapeutics Program Direct Costs Down-Regulation Doxorubicin Drops Drosophila genus Drug Formulations E2F Transcription Factor 1 Educational workshop Efaproxiral Effectiveness Enzymatic Biochemistry Enzymes Epidermal Growth Factor Receptor Eukaryotic Cell Exploratory/Developmental Grant for Diagnostic Cancer Imaging Faculty Funding Future Gap Junctions Geminin Gene Expression Profile Gene Mutation Gene Targeting Genetic Genetic Recombination Genetic Transcription Goals Grant Growth Guanine H-DNA Head Head and Neck Cancer Head and neck structure Hemoglobin Hospitals Human Engineering Human Resources Hypersensitivity Hypoxia Image Infiltration Insulin-Like-Growth Factor I Receptor Investigation Ionizing radiation Joints Journals Laboratories Lead Leadership Lesion Linear Accelerator Radiotherapy Systems MEN1 gene MLH1 gene Magnetic Resonance Imaging Maintenance Malignant Neoplasms Malignant Squamous Cell Neoplasm Malignant neoplasm of prostate Mammalian Cell Medical Medicine Menopausal Symptom Metastatic malignant neoplasm to brain Methods Mismatch Repair Mitomycins Molecular Molecular Virology Morbidity - disease rate Multiple Endocrine Neoplasia Type 1 Mus Mutagenesis Mutation Nature New England Normal tissue morphology Nucleotide Excision Repair O(6)-Methylguanine-DNA Methyltransferase Oligonucleotides Oncogenic Oral Outcome Oxygen PHY 906 Paper Pathway interactions Patients Pattern Peer Review Pelvis Peptide Nucleic Acids Pharmaceutical Preparations Pharmacologic Substance Pharmacology Phase Phase III Clinical Trials Physicians Physics Play Poly(ADP-ribose) Polymerases Polymerase Polyploidy Porfiromycin Positioning Attribute Process Prodrugs Production Program Research Project Grants Property Prostate Proteins Proteolysis Publications Published Comment Publishing RSR-13 Rad51 recombinase Radiation Radiation Tolerance Radiation Toxicity Radiation therapy Radio Radiobiology Radiometry Randomized Clinical Trials Reaction Recruitment Activity Regulation Regulatory Pathway Repair Complex Reporter Genes Reporting Research Research Personnel Resistance Resource Sharing Ribonucleoproteins Ribonucleotide Reductase Subunit Ribosomes Role Running Salmonella Schools Science Scientist Seeds Series Signal Transduction Pathway Site Skin Carcinogenesis Solid Neoplasm Son Source Specificity Structure Sunburn System TP53 gene Techniques Testing Therapeutic Therapeutic Radiology specialty Thymidine Phosphorylase Tissues Training Translational Research Treatment Protocols Triapine Tumor Biology Tumor Oxygenation Tumor Stem Cells UV induced United States National Institutes of Health Variant Viral Vision Work X-Ray Computed Tomography Yale Cancer Center Yeasts anticancer research base cancer cell differentiation cancer genetics cancer radiation therapy cancer therapy capecitabine carcinogenesis cell growth cell growth regulation cell transformation chemotherapy chromosome replication clinical practice cone-beam computed tomography cost cytotoxic detector dosimetry fluoropyrimidine helicase immunoregulation improved in vivo indexing inhibitor/antagonist interest irradiation malignant breast neoplasm meetings member metaplastic cell transformation millimeter molecular marker mouse model mutant neoplastic novel oncology particle population based post-doctoral training pre-clinical preclinical study prognostic programs recombinase repaired research study response square foot treatment duration treatment planning triplex DNA tumor tumor progression ubiquitin-protein ligase ultraviolet damage

项目摘要

The Program in Radiobiology and Radiotherapy (R&R) comprises a broadly based, multifaceted research effort in radiation therapy, radiation biology, radiological physics and related areas of tumor biology. This program has been an approved component of the Cancer Center Core Grant for over 20 years. Its long-term goal is to improve the treatment of cancer in general and in particular, the effectiveness of radiation therapy The program includes a broad spectrum of activity that extends from laboratory-based experimental research to clinical investigation and features investigators associated with eight departments. Some of the key themes include studies of carcinogenesis, genetic instability and cell growth control; elucidation of DNA repaii pathways; investigation of tumor hypoxia and testing of hypoxia-targeted cancer therapies in clinical trials molecular correlations with outcomes in radiation therapy, and improvements in radiation dosimetry, imaging and delivery. The majority of the members of the program have rich interactions with the Yale Cancer Cente (YCC) membership in several programs. Those interactions stimulate translational research that is in turr facilitated by other YCC Research Programs and by extensive use of Shared Resources. The numerous cancer-related grand rounds, seminars, meetings, and journal clubs sponsored by the YCC, along with the weekly Radiobiology Workshop and Journal Club and the weekly Therapeutic Radiology Grand Rounds sponsored by the program encourage the cooperation, mutual support, and cross stimulation among the component research teams, which leads to a more rapid and efficient application of the results of the research to clinical practice. Dr. Peter M. Glazer took over as Program Leader in 2002, replacing Dr. James J. Fischer, who had served as Program Leader since its inception. Dr. Patrick Sung, recruited to Yale in 2003, serves as co-Leader. Unde the new leadership, the Program has expanded to include a total of 25 faculty affiliated with nine departments and two schools, has played a role in recruiting three basic scientists and three physician investigators, anc has initiated renovation of 15,500 net square feet of laboratory space, partially funded by a $2.0 millior construction grant from the NIH awarded in 2003. Dr. Glazer also serves as PI of a T32 post-doctoral training grant in Radiation Therapy, Biology and Physics, which includes a number of YCC members both within anc outside of the Program. Since 1998, there have been 371 cancer-related publications, including 18% intra- anc 20% inter-programmatic collaborations. Overall, the 25 investigators associated with the program have peer reviewed funding of $4.1 M in annual direct costs ($6.4 M in annual total costs), including 17 R01s. Of this funding, $2.0 M (annual direct costs) comes from the NCI, including 10 R01s and the T32 training grant.

放射生物学和放射治疗（R＆R）的计划包括一项基于广泛的多方面研究放射治疗，放射生物学，放射学物理学和肿瘤生物学相关领域的努力。这 20多年来，计划已成为癌症中心核心赠款的批准组成部分。它的长期目标是改善癌症的治疗，尤其是放射治疗的有效性该计划包括广泛的活动，该活动从基于实验室的实验研究延伸临床调查和与八个部门相关的研究人员。一些关键主题包括癌变，遗传不稳定性和细胞生长控制的研究；阐明DNA repaii 途径；研究肿瘤缺氧和临床试验中低氧靶向癌症疗法的测试与放射疗法的结局的分子相关性，并改善辐射剂量法，成像和交付。该计划的大多数成员与耶鲁癌症百分之十（YCC）几个程序的会员资格。这些相互作用刺激了Turr中的转化研究通过其他YCC研究计划和大量使用共享资源来促进。众多 YCC赞助的与癌症相关的大回合，研讨会，会议和期刊俱乐部以及每周放射生物学研讨会和期刊俱乐部以及每周的治疗放射学大弹该计划赞助的鼓励合作，相互支持和交叉刺激组件研究团队，导致研究结果的更快，更有效地应用进行临床实践。彼得·格拉泽（Peter M. Glazer）博士于2002年接任计划负责人，取代了曾担任的詹姆斯·J·菲舍尔（James J. Fischer）博士计划负责人自成立以来。帕特里克·昂格（Patrick Sung）博士于2003年招募到耶鲁大学，担任共同领导。 UNDE 该计划的新领导已扩展到包括九个部门的25位教职员工两所学校在招募三位基本科学家和三名医师研究人员ANC中发挥了作用已开始翻新15,500平方英尺的实验室空间，部分由$ 2.0毫米资助 2003年授予的NIH的建筑赠款。Glazer博士还担任T32博士后培训的PI 放射疗法，生物学和物理学的授予，其中包括ANC内的许多YCC成员在程序之外。自1998年以来，已有371个与癌症相关的出版物，其中包括18％的内部。 20％的程序间合作。总体而言，与该计划相关的25位调查人员有同行审查了年度直接成本4.1 m $ 4.1 m的资金（年度总成本为6.4 m），其中包括17 r01。这资金为2.0 m（年度直接费用）来自NCI，其中包括10 R01和T32培训补助金。